Journal of Liver

Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis

3^rd World Congress on Hepatitis and Liver Diseases

October 10-12, 2016 Dubai, UAE

Ligita Jancoriene, Katazyna Polubenko, Edita Kazenaite, Arida Buivydiene, Jolita Jakutiene, Ieva Tolmane and Agita Jeruma

Vilnius University Hospital Santariskiu Klinikos, Lithuania
Vilnius University, Lithuania
Riga East University Hospital, Latvia

Scientific Tracks Abstracts: J Liver

Abstract:

The aim of multicenter, international, real-life study was to evaluate efficacy and safety of Ombitasvir/Paritaprevir/ Ritonavir+Dasabuvir±Ribavirin in treatment-naive and treatment-experienced GT1-infected patients, who failed previous PEG-INF/RBV±first generation protease inhibitor therapy. 114 (54 males) GT1-infected (102-GT1b) patients, aged 54.4±10.6 years, were included. 28.1% were treatment-naive, 71.9% treatment-experienced. 21 patients failed previous triple therapy with telaprevir or boceprevir. 57% were cirrhotics. Treatment was scheduled for 12 weeks in 112, 24 weeks in 2 patients. RBV was administered to 89 patients. Sustained virologic response (SVR12) was assessed by HCV-RNA undetectability 12 weeks after the end of treatment (EOT). 111 patients completed therapy and had undetectable HCV-RNA at the EOT. 73 patients with available follow-up evaluation achieved SVR12. The average reduction in alpha-fetoprotein (16.3 versus 4.9, p<0.001) and hepatic fibrosis (17.3 versus 15.5, p<0.001) was demonstrated at the end of follow-up. RBV was reduced in 18, discontinued in 11 patients. The most frequent adverse events were asthenia (25.4%), fatigue (15.8%), itching (13.2%) and dyspepsia (11.4%). Treatment was discontinued in 3 patients due to exacerbation of psoriasis (day 3), depression (week 5) and elevation of ALT, AST (week 9). 10 liver transplant patients received 24 weeks treatment (4 males, 50.7±8.0 years, 9-GT1b, 8-treatment-experienced). RBV was administered to 9, reduced in 3, discontinued in 2 patients. All patients completed therapy and had undetectable HCV-RNR at the EOT. 9 patients with available follow-up evaluation achieved SVR12. In conclusion, treatment with Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin achieved 100% SVR12. Adverse events were mostly mild and related to RBV administration.

Biography :

Ligita Jancoriene was graduated from Vilnius University Medical Faculty in 1989 and completed her Residency in Gastroenterology (1993). During her PhD studies she received Clinical Training in Infectious Diseases at Karolinska Institutet, Huddinge University Hospital, Sweden (1999-2003) and defended PhD thesis in a field of Infectious Diseases and Hepatology on the Management of Chronic Viral Hepatitis C (2003). She is working at the Department of Infectious diseases of Vilnius University since 1997 and also working as a Specialist of Infectious diseases and Gastroenterology at the Centre of Infectious diseases in the Vilnius University Hospital Santarisiu Klinikos since 1996. Currently, she is a Professor at the Department of Infectious, Chest diseases, Dermatovenerology and Allergology of Vilnius University and Head of the Department for Consultation and Immunoprophylaxis at the Centre of Infectious diseases in the Vilnius University Hospital Santariškių Klinikos. She is a Member of the European Association of the Study of the Liver and International Society of Travel Medicine. She is a Board Member of the Lithuanian Society of Infectious Diseases and Baltic Immunoprophylaxis Association. She is a co-author of scientific papers in peer-reviewed journals on vaccination and treatment of chronic viral hepatitis C. She was a Principal Investigator in more than 20 clinical trials on viral hepatitis and influenza treatment and vaccination.

Email: ligita.jancoriene@santa.lt